Study S003329

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06254274
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 210
Start: 2024-02-26
Primary completion: 2025-12-20
Lead sponsor: Guangdong Raynovent Biotech Co., Ltd
Conditions: T2DM (Type 2 Diabetes Mellitus)
Interventions: DRUG:RAY1225; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Change From Baseline in Hemoglobin A1c (HbA1c) [Baseline,Week 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.